dasiglucagon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Glucagon-like Peptide (GLP) analogues 5447 1544300-84-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasiglucagon
  • dasiglucagon hydrochloride
  • zegalogue
  • ZP4207
Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect.
  • Molecular weight: 3381.66
  • Formula: C152H222N38O50
  • CLOGP:
  • LIPINSKI: 3
  • HAC: 88
  • HDO: 52
  • TPSA: 1448.19
  • ALOGS: -4.74
  • ROTB: 109

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 22, 2021 FDA ZEALAND PHARMA AS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA PE N0000009345 Increased Glycogenolysis
FDA EPC N0000190852 Antihypoglycemic Agent
FDA MoA N0000193923 Glucagon Receptor Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypoglycemia due to diabetes mellitus indication 237633009
Insulinoma contraindication 302822000 DOID:3892
Pheochromocytoma contraindication 302835009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) ZEGALOGUE ZEALAND PHARMA N214231 March 22, 2021 RX SOLUTION SUBCUTANEOUS March 22, 2026 NEW CHEMICAL ENTITY
EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) ZEGALOGUE (AUTOINJECTOR) ZEALAND PHARMA N214231 March 22, 2021 RX SOLUTION SUBCUTANEOUS March 22, 2026 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon receptor GPCR AGONIST EC50 11 DRUG LABEL DRUG LABEL

External reference:

IDSource
D11359 KEGG_DRUG
AD4J2O47FQ UNII
C5139868 UMLSCUI
CHEMBL4297741 ChEMBL_ID
126961379 PUBCHEM_CID
DB15226 DRUGBANK_ID
CHEMBL4650274 ChEMBL_ID
2535233 RXNORM
39407 MMSL
d09724 MMSL
4040381 VANDF
018680 NDDF
018681 NDDF
C000710373 MESH_SUPPLEMENTAL_RECORD_UI
10480 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zegalogue HUMAN PRESCRIPTION DRUG LABEL 1 80644-0012 INJECTION, SOLUTION 0.60 mg SUBCUTANEOUS NDA 30 sections
Zegalogue HUMAN PRESCRIPTION DRUG LABEL 1 80644-0012 INJECTION, SOLUTION 0.60 mg SUBCUTANEOUS NDA 30 sections
Zegalogue HUMAN PRESCRIPTION DRUG LABEL 1 80644-0013 INJECTION, SOLUTION 0.60 mg SUBCUTANEOUS NDA 30 sections
Zegalogue HUMAN PRESCRIPTION DRUG LABEL 1 80644-0013 INJECTION, SOLUTION 0.60 mg SUBCUTANEOUS NDA 30 sections